1419213-58-3

Upstream product

• 55557-52-3 2-chloro-3-cyanopyrazine 
• 1419221-23-0 (trans)-4-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclohexyl acetate 
• 1326280-88-9 (trans)-4-((3-chloropyrazin-2-yl)methylcarbamoyl)cyclohexyl acetate 
• 1326280-86-7 (trans)-N-((3-chloropyrazin-2-yl)methyl)-4-hydroxycyclohexanecarboxamide 
• 850568-25-1 4-(pyridin-2-yl-aminocarbonyl)benzeneboronic acid 
• 1419221-24-1 (trans)-4-(8-amino-1-bromoimidazol[1,5-a]pyrazin-3-yl)cyclohexyl acetate 

Relevant academic research and scientific papers

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

BTK INHIBITORS

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.